GB0226722D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB0226722D0
GB0226722D0 GBGB0226722.7A GB0226722A GB0226722D0 GB 0226722 D0 GB0226722 D0 GB 0226722D0 GB 0226722 A GB0226722 A GB 0226722A GB 0226722 D0 GB0226722 D0 GB 0226722D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0226722.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0226722.7A priority Critical patent/GB0226722D0/en
Publication of GB0226722D0 publication Critical patent/GB0226722D0/en
Priority to AU2003288084A priority patent/AU2003288084A1/en
Priority to TW092131802A priority patent/TW200502246A/zh
Priority to RU2005113691/13A priority patent/RU2363492C2/ru
Priority to US10/535,047 priority patent/US20060246090A1/en
Priority to NZ539999A priority patent/NZ539999A/en
Priority to CNA200380108865XA priority patent/CN1738833A/zh
Priority to JP2004552621A priority patent/JP2006524181A/ja
Priority to JP2004552615A priority patent/JP2006518331A/ja
Priority to MXPA05005202A priority patent/MXPA05005202A/es
Priority to BR0316244-3A priority patent/BR0316244A/pt
Priority to PL376967A priority patent/PL376967A1/pl
Priority to KR1020057008794A priority patent/KR20050085010A/ko
Priority to AU2003288072A priority patent/AU2003288072A1/en
Priority to EP03779938A priority patent/EP1560844A1/en
Priority to PCT/EP2003/012830 priority patent/WO2004046176A1/en
Priority to US10/534,774 priority patent/US20060135451A1/en
Priority to MXPA05005203A priority patent/MXPA05005203A/es
Priority to PL376882A priority patent/PL376882A1/pl
Priority to CNA2003801088698A priority patent/CN1738834A/zh
Priority to CA002504715A priority patent/CA2504715A1/en
Priority to KR1020057008793A priority patent/KR20050085009A/ko
Priority to NZ539998A priority patent/NZ539998A/en
Priority to RU2005113692/13A priority patent/RU2323744C2/ru
Priority to CA002504654A priority patent/CA2504654A1/en
Priority to BR0316291-5A priority patent/BR0316291A/pt
Priority to EP03779952A priority patent/EP1560845A1/en
Priority to ARP030104193A priority patent/AR041964A1/es
Priority to PCT/EP2003/012793 priority patent/WO2004046175A1/en
Priority to IS7831A priority patent/IS7831A/is
Priority to IS7830A priority patent/IS7830A/is
Priority to NO20052149A priority patent/NO20052149L/no
Priority to NO20052136A priority patent/NO20052136L/no
Priority to ZA200503802A priority patent/ZA200503802B/en
Priority to ZA200503803A priority patent/ZA200503803B/en
Priority to MA28285A priority patent/MA27700A1/fr
Priority to MA28284A priority patent/MA27699A1/fr
Priority to CO05056623A priority patent/CO5700833A2/es
Priority to US12/174,715 priority patent/US20090104231A1/en
Priority to US12/471,772 priority patent/US20090232847A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
GBGB0226722.7A 2002-11-15 2002-11-15 Vaccine Ceased GB0226722D0 (en)

Priority Applications (40)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine
PCT/EP2003/012793 WO2004046175A1 (en) 2002-11-15 2003-11-13 Vaccine
PL376882A PL376882A1 (pl) 2002-11-15 2003-11-13 Szczepionka
CNA2003801088698A CN1738834A (zh) 2002-11-15 2003-11-13 Hcv 疫苗
RU2005113691/13A RU2363492C2 (ru) 2002-11-15 2003-11-13 Вакцина
US10/535,047 US20060246090A1 (en) 2002-11-15 2003-11-13 Vaccine against hcv
NZ539999A NZ539999A (en) 2002-11-15 2003-11-13 A polynucleotide vaccine comprising a polynucleotide sequence that encodes the HCV core protein and a polynucleotide that encodes at least one other HCV protein
CNA200380108865XA CN1738833A (zh) 2002-11-15 2003-11-13 Hcv疫苗
JP2004552621A JP2006524181A (ja) 2002-11-15 2003-11-13 ワクチン
JP2004552615A JP2006518331A (ja) 2002-11-15 2003-11-13 ワクチン
MXPA05005202A MXPA05005202A (es) 2002-11-15 2003-11-13 Vacuna.
BR0316244-3A BR0316244A (pt) 2002-11-15 2003-11-13 Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
PL376967A PL376967A1 (pl) 2002-11-15 2003-11-13 Szczepionka przeciw HCV
KR1020057008794A KR20050085010A (ko) 2002-11-15 2003-11-13 백신
AU2003288072A AU2003288072A1 (en) 2002-11-15 2003-11-13 Vaccine
EP03779938A EP1560844A1 (en) 2002-11-15 2003-11-13 Hepatitis c vaccine
TW092131802A TW200502246A (en) 2002-11-15 2003-11-13 Vaccine
US10/534,774 US20060135451A1 (en) 2002-11-15 2003-11-13 Vaccine
MXPA05005203A MXPA05005203A (es) 2002-11-15 2003-11-13 Vacuna contra vhc.
AU2003288084A AU2003288084A1 (en) 2002-11-15 2003-11-13 Vaccine against hcv
CA002504715A CA2504715A1 (en) 2002-11-15 2003-11-13 Vaccine
PCT/EP2003/012830 WO2004046176A1 (en) 2002-11-15 2003-11-13 Vaccine against hcv
EP03779952A EP1560845A1 (en) 2002-11-15 2003-11-13 Vaccine against hcv
NZ539998A NZ539998A (en) 2002-11-15 2003-11-13 Vaccine against HCV comprising a polynucleotide that encodes the sequences of HCV proteins: core, NS3, NS4b and NS5b and no other proteins.
RU2005113692/13A RU2323744C2 (ru) 2002-11-15 2003-11-13 Вакцина против hcv
CA002504654A CA2504654A1 (en) 2002-11-15 2003-11-13 Vaccine against hcv
BR0316291-5A BR0316291A (pt) 2002-11-15 2003-11-13 Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
KR1020057008793A KR20050085009A (ko) 2002-11-15 2003-11-13 Ｈｃｖ에 대한 백신
ARP030104193A AR041964A1 (es) 2002-11-15 2003-11-13 Vacuna de vhc que comprende un polinucleotido
IS7830A IS7830A (is) 2002-11-15 2005-04-28 Bóluefni gegn lifrarbólgu C veiru (HCV)
IS7831A IS7831A (is) 2002-11-15 2005-04-28 Bóluefni
NO20052149A NO20052149L (no) 2002-11-15 2005-05-02 Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.
NO20052136A NO20052136L (no) 2002-11-15 2005-05-02 Vaksine mot Hepatitt C-virus (HCV).
ZA200503802A ZA200503802B (en) 2002-11-15 2005-05-11 Vaccine against HCV
ZA200503803A ZA200503803B (en) 2002-11-15 2005-05-11 Vaccine
MA28285A MA27700A1 (fr) 2002-11-15 2005-05-16 Vaccin contre l'hepatite c
MA28284A MA27699A1 (fr) 2002-11-15 2005-05-16 Vaccin contre vhc
CO05056623A CO5700833A2 (es) 2002-11-15 2005-06-10 Vacuna
US12/174,715 US20090104231A1 (en) 2002-11-15 2008-07-17 Vaccine
US12/471,772 US20090232847A1 (en) 2002-11-15 2009-05-26 Immunogenic compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
GB0226722D0 true GB0226722D0 (en) 2002-12-24

Family

ID=9947928

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0226722.7A Ceased GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Country Status (21)

Country Link
US (4) US20060135451A1 (enExample)
EP (2) EP1560844A1 (enExample)
JP (2) JP2006524181A (enExample)
KR (2) KR20050085009A (enExample)
CN (2) CN1738834A (enExample)
AR (1) AR041964A1 (enExample)
AU (2) AU2003288084A1 (enExample)
BR (2) BR0316291A (enExample)
CA (2) CA2504715A1 (enExample)
CO (1) CO5700833A2 (enExample)
GB (1) GB0226722D0 (enExample)
IS (2) IS7830A (enExample)
MA (2) MA27700A1 (enExample)
MX (2) MXPA05005203A (enExample)
NO (2) NO20052149L (enExample)
NZ (2) NZ539998A (enExample)
PL (2) PL376967A1 (enExample)
RU (2) RU2363492C2 (enExample)
TW (1) TW200502246A (enExample)
WO (2) WO2004046176A1 (enExample)
ZA (2) ZA200503803B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
CA2645177A1 (en) * 2006-03-09 2007-09-13 Transgene S.A. Hepatitis c virus non structural fusion protein
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
WO2008094197A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US20120100170A1 (en) * 2008-07-24 2012-04-26 Lauer Peter M Compositions and methods for the treatment of hepatitis c
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
WO2014127478A1 (en) * 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IE62868B1 (en) * 1987-11-18 1995-03-08 Chiron Corp Hepatitis C virus
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
DE69533167D1 (de) * 1994-10-05 2004-07-22 Apollon Inc Impfstoffe gegen den hepatitis b und c virus
IL118364A0 (en) * 1995-05-22 1996-09-12 Bionova Corp A hepatitis C virus-derived composition methods for the preparation thereof and assays for the detection of hepatitis C virus
JP2002500502A (ja) * 1996-06-11 2002-01-08 メルク エンド カンパニー インコーポレーテッド 合成ｃ型肝炎遺伝子
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
AU774887B2 (en) * 1999-07-09 2004-07-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
EP1233982B1 (en) * 1999-11-24 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Novel hcv non-structural polypeptide
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2005113692A (ru) 2006-01-27
NZ539999A (en) 2008-03-28
CA2504654A1 (en) 2004-06-03
PL376882A1 (pl) 2006-01-09
AU2003288084A1 (en) 2004-06-15
TW200502246A (en) 2005-01-16
BR0316244A (pt) 2005-10-04
CN1738834A (zh) 2006-02-22
MA27699A1 (fr) 2006-01-02
MXPA05005202A (es) 2006-01-27
AU2003288072A1 (en) 2004-06-15
BR0316291A (pt) 2005-10-11
WO2004046176A1 (en) 2004-06-03
WO2004046175A1 (en) 2004-06-03
NO20052136L (no) 2005-07-11
MA27700A1 (fr) 2006-01-02
RU2005113691A (ru) 2006-01-27
EP1560844A1 (en) 2005-08-10
CA2504715A1 (en) 2004-06-03
MXPA05005203A (es) 2006-01-27
US20060246090A1 (en) 2006-11-02
KR20050085010A (ko) 2005-08-29
US20090104231A1 (en) 2009-04-23
US20090232847A1 (en) 2009-09-17
IS7830A (is) 2005-04-28
KR20050085009A (ko) 2005-08-29
ZA200503803B (en) 2006-08-30
CO5700833A2 (es) 2006-11-30
US20060135451A1 (en) 2006-06-22
NO20052136D0 (no) 2005-05-02
JP2006524181A (ja) 2006-10-26
PL376967A1 (pl) 2006-01-23
RU2323744C2 (ru) 2008-05-10
EP1560845A1 (en) 2005-08-10
IS7831A (is) 2005-04-28
NO20052149L (no) 2005-07-11
RU2363492C2 (ru) 2009-08-10
NZ539998A (en) 2008-04-30
ZA200503802B (en) 2006-08-30
AR041964A1 (es) 2005-06-01
JP2006518331A (ja) 2006-08-10
NO20052149D0 (no) 2005-05-02
CN1738833A (zh) 2006-02-22

Similar Documents

Publication Publication Date Title
GB0213622D0 (en) Vaccine Corporation
GB0226722D0 (en) Vaccine
GB0202901D0 (en) Novel vaccine
GB0329146D0 (en) Vaccine
GB0225788D0 (en) Vaccine
GB0225786D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0228715D0 (en) Vaccine
GB0209878D0 (en) Vaccine
GB0218921D0 (en) Novel vaccine
PL376534A1 (pl) Szczepionka
IL173921A0 (en) Vaccine
GB0305794D0 (en) Vaccine
GB0330079D0 (en) Vaccine
GB0305793D0 (en) Vaccine
GB0212036D0 (en) Vaccines
GB0206595D0 (en) Vaccine
IL156434A0 (en) Vaccine
GB0223355D0 (en) Vaccine
GB0226179D0 (en) Vaccine
GB0221689D0 (en) Vaccine
GB0220211D0 (en) Vaccine
GB0229594D0 (en) Vaccine
GB0227619D0 (en) Vaccine
GB0228714D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)